대한갑상선학회 갑상선분화암 진료권고안; Part I. 갑상선분화암의 초기치료 - 제4장 갑상선분화암의 수술 후 병리학적 진단 및 병기 결정 2024
Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 4. Pathological Diagnosis and Staging after Thyroidectomy 2024
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Postoperative pathological diagnosis of differentiated thyroid cancer (DTC) is important to confirm the diagnosis and predict the risk of recurrence and death. Further treatment plans, such as completion thyroidectomy, radioiodine remnant ablation, or external beam radiation therapy, are then opted for to reduce the predicted risk of recurrence or death. The World Health Organization has classified thyroid cancers into seven distinct categories based on the molecular profile and tumor cell origin. Our recommendation is applicable to differentiated follicular cell-derived carcinoma, the most common form of thyroid cancer, and cribriform morular thyroid carcinoma. Postoperative clinical and pathological staging is recommended for all patients with DTC to determine their prognosis and subsequent treatment decisions. In particular, the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system is recommended for staging DTCs for disease mortality prediction and national cancer registries. The information in the pathology report, including histologic features of the tumor that are necessary for AJCC/UICC staging and recurrence prediction, can help assess the patient’s risk.
Abstract
Postoperative pathological diagnosis of differentiated thyroid cancer (DTC) is important to confirm the diagnosis and predict the risk of recurrence and death. Further treatment plans, such as completion thyroidectomy, radioiodine remnant ablation, or external beam radiation therapy, are then opted for to reduce the predicted risk of recurrence or death. The World Health Organization has classified thyroid cancers into seven distinct categories based on the molecular profile and tumor cell origin. Our recommendation is applicable to differentiated follicular cell-derived carcinoma, the most common form of thyroid cancer, and cribriform morular thyroid carcinoma. Postoperative clinical and pathological staging is recommended for all patients with DTC to determine their prognosis and subsequent treatment decisions. In particular, the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system is recommended for staging DTCs for disease mortality prediction and national cancer registries. The information in the pathology report, including histologic features of the tumor that are necessary for AJCC/UICC staging and recurrence prediction, can help assess the patient’s risk.
참고문헌 (28)
- Jung CK, "Update from the 2022 World Health Organization classification of thyroid tumors : a standardized diagnostic approach", Endocrinol Metab(Seoul), 37(5), pp.703~718 (2022)
- Baloch ZW, "Overview of the 2022 WHO classification of thyroid neoplasms", Endocr Pathol, 33(1), pp.27~63 (2022)
- Brierley JD, "A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example", Cancer, 79(12), pp.2414~2423 (1997)
- Loh KC, "Pathological tumor-node-metastasis(pTNM)staging for papillary and follicular thyroid carcinomas : a retrospective analysis of 700patients", J Clin Endocrinol Metab, 82(11), pp.3553~3562 (1997)
- Asa SL, "Medullary thyroid carcinoma in the IARC", WHO neuroendocrine schema, 2022, pp.33(3), 346~347
- Hellgren LS, "Prognostic utility of the Ki-67 labeling index in follicular thyroid tumors : a 20-year experience from a tertiary thyroid center", Endocr Pathol, 33(2), pp.231~242 (2022)
- Bai Y, "Updates in the pathologic classification of thyroid neoplasms : a review of the World Health Organization classification", Endocrinol Metab(Seoul), 35(4), pp.696~715 (2020)
- Lomnitzer R, "Low specific IgE, IgG and lymphocyte reactivity in a group of patients developing anaphylaxis following a honey-bee sting", Clin Allergy, 18(1), pp.39~44 (1988)
- Harach HR, "Familial adenomatous polyposis associated thyroid carcinoma : a distinct type of follicular cell neoplasm", Histopathology, 25(6), pp.549~561 (1994)
- Cameselle-Teijeiro J, "Cribriform-morular variant of papillary carcinoma : a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma?", Mod Pathol, 12(4), pp.400~411 (1999)
- Boyraz B, "Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis", Endocr Pathol, 32(3), pp.327~335 (2021)
- Harach HR, "Thyroid pathologic findings in patients with Cowden disease", Ann Diagn Pathol, 3(6), pp.331~340 (1999)
- Cameselle-Teijeiro J, "Thyroid pathology findings in cowden syndrome : a clue for the diagnosis of the PTEN hamartoma tumor syndrome", Am J Clin Pathol, 144(2), pp.322~328 (2015)
- Szabo Yamashita T, "Occurrence and natural history of thyroid cancer in patients with Cowden syndrome", Eur Thyroid J, 9(5), pp.243~246 (2020)
- Laury AR, "Thyroid pathology in PTEN-hamartoma tumor syndrome : characteristic findings of a distinct entity", Thyroid, 21(2), pp.135~144 (2011)
- Smith JR, "Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome", J Clin Endocrinol Metab, 96(1), pp.34~37 (2011)
- Nose V, "Thyroid cancer of follicular cell origin in inherited tumor syndromes", Adv Anat Pathol, 17(6), pp.428~436 (2010)
- Milas M, "Should patients with Cowden syndrome undergo prophylactic thyroidectomy?", Surgery, 152(6), pp.1201~1210 (2012)
- Hall JE, "Thyroid disease associated with Cowden syndrome : a meta-analysis", Head Neck, 35(8), pp.1189~1194 (2013)
- Guilmette J, "Hereditary and familial thyroid tumours", Histopathology, 72(1), pp.70~81 (2018)
- Ni Y, "Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD", NAD-dependant destabilization of p53, 2012, pp.21(2), 300~310
- Yehia L, "PTEN hamartoma tumour syndrome : what happens when there is no PTEN germline mutation?", Hum Mol Genet, 29(R2), pp.R150~R157 (2020)
- Bertherat J, "Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase(PRKAR1A) : phenotype analysis in 353 patients and 80 different genotypes", J Clin Endocrinol Metab, 94(6), pp.2085~2091 (2009)
- Barletta JA, "Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome", Am J Surg Pathol, 35(10), pp.1505~1511 (2011)